USA - NYSE:ANRO - US02157Q1094 - Common Stock
The current stock price of ANRO is 3.94 USD. In the past month the price increased by 0.28%. In the past year, price decreased by -73.7%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 46.75 | 714.52B | ||
JNJ | JOHNSON & JOHNSON | 17.42 | 419.61B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 15.27 | 266.61B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 17.51 | 241.00B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.96 | 239.21B | ||
MRK | MERCK & CO. INC. | 10.46 | 201.08B | ||
PFE | PFIZER INC | 7.1 | 136.85B | ||
SNY | SANOFI-ADR | 10.58 | 114.84B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.69 | 91.67B | ||
GSK | GSK PLC-SPON ADR | 9.06 | 82.47B | ||
ZTS | ZOETIS INC | 23.29 | 64.19B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.81 | 47.45B |
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 76 full-time employees. The company went IPO on 2024-02-02. The firm's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
ALTO NEUROSCIENCE INC
650 Castro Street, Suite 450
Mountain View CALIFORNIA US
Employees: 76
Phone: 17732555012
The current stock price of ANRO is 3.94 USD. The price increased by 9.44% in the last trading session.
The exchange symbol of ALTO NEUROSCIENCE INC is ANRO and it is listed on the New York Stock Exchange, Inc. exchange.
ANRO stock is listed on the New York Stock Exchange, Inc. exchange.
14 analysts have analysed ANRO and the average price target is 10.54 USD. This implies a price increase of 167.51% is expected in the next year compared to the current price of 3.94. Check the ALTO NEUROSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ALTO NEUROSCIENCE INC (ANRO) has a market capitalization of 106.70M USD. This makes ANRO a Micro Cap stock.
ALTO NEUROSCIENCE INC (ANRO) currently has 76 employees.
ALTO NEUROSCIENCE INC (ANRO) has a support level at 3.5 and a resistance level at 3.91. Check the full technical report for a detailed analysis of ANRO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ANRO does not pay a dividend.
ALTO NEUROSCIENCE INC (ANRO) will report earnings on 2025-11-12, after the market close.
ALTO NEUROSCIENCE INC (ANRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.39).
The outstanding short interest for ALTO NEUROSCIENCE INC (ANRO) is 6.86% of its float. Check the ownership tab for more information on the ANRO short interest.
ChartMill assigns a technical rating of 6 / 10 to ANRO. When comparing the yearly performance of all stocks, ANRO is a bad performer in the overall market: 81.02% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ANRO. The financial health of ANRO is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ANRO reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS increased by 13.41% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -41.08% | ||
ROE | -52.55% | ||
Debt/Equity | 0.18 |
14 analysts have analysed ANRO and the average price target is 10.54 USD. This implies a price increase of 167.51% is expected in the next year compared to the current price of 3.94.